Market
Main competitive advantage of orforglipron by end of 2026
2
Resolution / Starting Odds
Convenience • 25%
Cost • 25%
Efficacy • 25%
Other advantage • 25%
Industry reports, expert analysis, and consumer surveys
Story
Eli Lilly Anticipates Approval for Orforglipron Weight-Loss Pill in Early 2026
Jan 13, 2025, 06:07 PM
Eli Lilly & Co. is anticipating regulatory approval for its experimental weight-loss pill, orforglipron, as early as early 2026, according to CEO Dave Ricks. Ricks, speaking at the JPMorgan Healthcare Conference in San Francisco, indicated that data on the pill is expected by mid-2025. He highlighted that the oral form of the drug would be more convenient for patients and easier to manufacture at a large scale compared to the company's current injectable weight-loss drugs, which have faced supply shortages due to production constraints.
View original story
Similar markets
Other • 25%
Eli Lilly • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
China • 25%
United States • 25%
European Union • 25%
None • 25%
Drug B • 25%
Drug C • 25%
None • 25%
Drug A • 25%
CTO • 25%
CFO • 25%
None • 25%
CEO • 25%
Pfizer • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Other • 25%
Multitask Language Understanding • 25%
Cost-effectiveness • 25%
Computational Efficiency • 25%
Mathematical Reasoning • 25%
20% to 40% • 25%
More than 60% • 25%
41% to 60% • 25%
Less than 20% • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Partnership with another biotech • 25%
Other strategic move • 25%
Focus on internal development • 25%
Another acquisition in oncology • 25%
No acquisitions completed • 25%
Successful acquisition of Sage Therapeutics • 25%
Successful acquisition of another biotech • 25%
Multiple acquisitions completed • 25%